New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
09:18 EDTMNKD, CRY, AGU, MYGN, APOL, VEEV, GSK, AGEN, ENVI, ICPT, CELG, XLRN, AMZN, AAPLOn The Fly: Pre-market Movers
HIGHER: MannKind (MNKD), up more than 88% after an FDA advisory panel voted in favor of its Afrezza to treat type 1 and type 2 diabetes... Acceleron Pharma (XLRN), up 14% after Celgene (CELG) strikes deal to buy 1.1M Acceleron shares for $47.15M... CryoLife (CRY), up 10% after receiving FDA approval to begin clinical trials for PerClot in the U.S... Veeva (VEEV), up 6% after upgraded at Morgan Stanley... Envivio (ENVI), up 18% after announcing that it is powering live HD sports channels for Apple TV (AAPL) for a "European Tier 1 service provider."... Myriad Genetics (MYGN), up 13% after disclosing updated pricing from the Centers for Medicare & Medicaid Services for the sequencing of BRCA1 and BRCA2 genes... Amazon (AMZN), up 0.75% ahead of media event in New York City, where company is expected to announce a media streaming device. LOWER: Apollo Education (APOL), down 3.7% following earnings, disclosure of subpoena... Agenus (AGEN), down 9% after GlaxoSmithKline (GSK) stops MAGRITi Phase 3 trial... Agrium (AGU), down 3% after warning that the late spring season this year is expected to impact the timing of its earnings... Intercept Pharmaceuticals (ICPT), down 4% after filing to sell 1M common shares, including 400,000 for shareholders.
News For MNKD;AMZN;XLRN;CELG;ICPT;ENVI;AGEN;GSK;VEEV;APOL;MYGN;AGU;CRY;AAPL From The Last 14 Days
Check below for free stories on MNKD;AMZN;XLRN;CELG;ICPT;ENVI;AGEN;GSK;VEEV;APOL;MYGN;AGU;CRY;AAPL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
August 19, 2014
17:14 EDTAAPLOn The Fly: Closing Wrap
Subscribe for More Information
16:00 EDTAAPLOptions Update; August 19, 2014eBay
iPath S&P 500 VIX Short-Term Futures down 28c to 27.52. Option volume leaders: AAPL C HD PBR GILD AA NFLX TWTR TSLA EBAY according to Track Data.
15:12 EDTAPOLApollo Education management to meet with Piper Jaffray
Meeting to be held in Los Angeles on August 21 hosted by Piper Jaffray.
14:19 EDTAAPLCarl Icahn says increased Apple position over past year
Carl Icahn tweeted in regards to Apple, "All my chips still on the table and in fact increased position over past year." Icahn added that anyone who invested in Apple last year when he recommended the stock would be up 53% including dividends.
13:54 EDTAAPLCarney a contender to take over top communications job at Apple, Re/code says
Subscribe for More Information
12:40 EDTAAPLApple nears life high, levels to watch
Subscribe for More Information
12:27 EDTAAPLIcahn says 'very sizable' shareholder of Apple, has not sold share
Subscribe for More Information
11:57 EDTAAPLApple shares reach $100, up 84c or 1%
10:42 EDTMNKDOptions with decreasing implied volatility
Subscribe for More Information
09:38 EDTAAPL, CELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA CELG VLO VZ FB HD
07:33 EDTCELGCelgene announces publication of REVLIMID combination results
Celgene announced that results of a study evaluating the combination of REVLIMID with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone in untreated diffuse large b-cell lymphoma were published online ahead of print in the Journal of Clinical Oncology. In a phase II, open label, single arm study, 64 patients with newly diagnosed, untreated, stage II-IV CD20 positive DLBCL received 25 mg of lenalidomide on days 1-10 with standard dose R-CHOP every 21 days for six cycles. All patients received pegfilgrastim on day two of each cycle and aspirin prophylaxis throughout. The primary endpoint was event-free survival with secondary endpoints of progression free survival and overall survival. A one-stage binomial design was used to assess the efficacy and tolerability of REVLIMID with R-CHOP. Of the 64 patients enrolled, 60 were eligible for response evaluation. In these patients, the overall response rate was 98% with 80% achieving a complete response. The 24-month EFS, which was identical to PFS, and OS rates were 59% and 78%, respectively. The company said, "This study demonstrated that the addition of lenalidomide to conventional R-CHOP resulted in similar PFS rates and OS rates between sub-types. This is intriguing as patients with the non-GCB phenotype have traditionally experienced poorer outcomes. The results of this study support further evaluation of this regimen in this sub-type of DLBCL.
06:57 EDTAMZNAmazon.com implied volatility of 22 at lower end of index mean range
Subscribe for More Information
06:32 EDTAAPLMorgan Stanley recommends adding to Apple positions
Subscribe for More Information
August 18, 2014
16:00 EDTAAPL, AMZNOptions Update; August 18, 2014
Subscribe for More Information
10:57 EDTICPTOptions with decreasing implied volatility
Subscribe for More Information
09:35 EDTAAPL, AMZNActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AMZN DG TSLA GILD FB ABX WFC C
08:30 EDTAAPLApple starts production of smartphones with sapphire screens, Guardian says
Subscribe for More Information
07:58 EDTAAPLApple December quarter EPS likely to beat by 10%+, says RBC Capital
Subscribe for More Information
06:42 EDTAAPLApple may call 5.5-inch iPhone '6L,' 9to5Mac reports
Apple may call its rumored 5.5-inch iPhone model the "6L," 9to5Mac reports, citing Asia-based rumor site Apple Daily. In this scenario, the 4.7-inch iPhone would be called the iPhone 6. Reference Link
05:23 EDTAAPLInvenSense downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded InvenSense (INVN) to Neutral citing valuation with shares near its $25 price target. Goldman also believes the near-term catalyst of share gains at Apple (AAPL) has passed. InvenSense closed Friday down 1c to $24.99.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use